In a recent case (judgment of 23 January 2018, case C-179/16, Hoffmann-La Roche and others), the Court of Justice held that an arrangement put in place between two undertakings marketing two competing products, which concerned the dissemination of misleading information relating to adverse reactions resulting from the use of one of those medicinal products, with a view to reducing competitive pressure, constituted a restriction of competition “by object” for the purposes of Art. 101, para. 1, TFEU. The purpose of this Insight is to provide an analysis of the case, focusing on both the opinion of the Advocate General and the judgment, and to provide further examples that prove that the dissemination of misleading information in the pharmaceutical field has become a competition law problem
F. Hoffmann-La Roche Ltd e altri: le informazioni ingannevoli possono nuocere alla salute… e alla concorrenza
Rosano' A
2018-01-01
Abstract
In a recent case (judgment of 23 January 2018, case C-179/16, Hoffmann-La Roche and others), the Court of Justice held that an arrangement put in place between two undertakings marketing two competing products, which concerned the dissemination of misleading information relating to adverse reactions resulting from the use of one of those medicinal products, with a view to reducing competitive pressure, constituted a restriction of competition “by object” for the purposes of Art. 101, para. 1, TFEU. The purpose of this Insight is to provide an analysis of the case, focusing on both the opinion of the Advocate General and the judgment, and to provide further examples that prove that the dissemination of misleading information in the pharmaceutical field has become a competition law problemI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
